Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients

Inclusion Criteria: * Patients suffering from their second recurrence of ovarian, fallopian tube or primary peritoneal cancer, with an elevated serum level of CA-125 on two successive time points with 28 days in between, reaching a value of more than 2 times nadir and above 35 U/ml without gastrointestinal symptoms. * Able to undergo laparoscopic IP port placement and IP treatment administration * Adequate organ function * Age 18 years or older * Age under 76 years. * Karnofsky performance status \>70% (see appendix 2) * Life expectancy \> 6 months * At least 28 days after last anti cancer treatment, before start of preparative regimen * Written informed consent * Availability of a partially HLA-matched UCB unit Exclusion Criteria: * Patients on immunosuppressive drugs * Patients with active infections (viral, bacterial or fungal) that requires specific therapy. Acute anti-infectious therapy must have been completed within 14 days prior to study treatment * Laparoscopic adhesion score \>4 out of 9. * Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease (appendix 4) * Severe pulmonary dysfunction (CTCAE III-IV) (appendix 4) * Severe renal dysfunction (MDRD\<50) (appendix 4) * Severe hepatic dysfunction (serum bilirubin or transaminases \> 3 times normal level) (appendix 4) * Severe neurological or psychiatric disease